Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral cancer vaccine V3-OVA
- Development stage
- Phase 2
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Oral cancer vaccine V3-OVA is an orally available therapeutic cancer vaccine composed of autologous ovarian cancer antigens. These antigens are obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer. The primary mechanism involves stimulating the immune system to recognize and attack ovarian tumor cells by presenting patient-specific tumor-associated antigens. This approach aims to induce a targeted anti-tumor immune response for the treatment of ovarian cancer[1].
- Other names
- oral cancer vaccine V3-OVA
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on Oral cancer vaccine V3-OVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oral cancer vaccine V3-OVA.